Latest Agenus News & Updates

See the latest news and media coverage for Agenus. We track all announcements, press releases, and industry mentions in real time, all in one place.

Agenus

Cancer immunotherapy company

agenusbio.com

Headquarters: Lexington, United States
Founded year: 1994
Company type: Public company
Number of employees: 200–500
Industry: Pharmaceuticals

Last updated Today

Latest news about Agenus

In short: Agenus reported a Q2 2026 profit and secured $340 million in funding to advance Phase 3 clinical trials for its BOT+BAL immunotherapy.

Company announcements

Today Agenus

Agenus publishes mature trial results for its immuno-oncology combination therapy

The peer-reviewed study demonstrates durable survival rates and efficacy in immunologically cold tumors, supporting evaluation in earlier disease stages.

August 26 Agenus

Agenus shares positive Phase 2 colon cancer trial data

Updates confirm deep pathologic responses and disease clearance without surgery delays, strengthening the case for the upcoming global Phase 3 ROBBIN study.

August 6 Agenus

Agenus reports second quarter 2026 results and advances ROBBIN trial

The company completed an $85 million private placement, expects ROBBIN initiation in Q1 2027, and reported $6.4 million in pre-commercial product revenue for Q2 2026.

July 28 Agenus

Agenus to provide second quarter 2026 financial report

Results release on August 6; webcast in August to discuss BOT+BAL and clinical milestones.

Media coverage

Today Yahoo Finance

Agenus Announces Peer-Reviewed Publication Linking BOT+BAL's Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of mature Phase 1b results from the fully enrolled C-800-01 cohort...

August 26 Yahoo Finance

Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of updated results from the investigator-sponsored Phase 2 NEST trial evaluating...

August 20 RTTNews

Agenus Reports Q2 Profit; Advances BOT+BAL Toward Phase 3 ROBBIN Trial

Agenus reported Q2 net income of $0.6M, reversing a $30M loss, while revenue rose to $34.5M. The company is advancing BOT+BAL toward the Phase 3...

August 12 Yahoo Finance

Agenus (AGEN) Stock Fair Value Falls After Analysts Rework Pipeline And Financing Assumptions

The latest analyst update on Agenus centers on a reset of its fair value estimate, with the price...

Never miss news about Agenus

Track Agenus and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Agenus competitors & trending companies

Browse news for competitors to Agenus and other trending companies.